Group items tagged

The Department of Health and Social Care (DHSC) has published the NIHR's annual report and accounts for 2023/24, highlighting a 4.2 per cent increase in total domestic research spending from the previous year. This increase has allowed the NIHR to improve investments in research funding, infrastructure, and training and career development initiatives. Additionally, the report showcases various research projects that are having a significant impact on people's lives now and in the future. Professor Lucy Chappell, Chief Scientific Advisor at DHSC and Chief Executive of the NIHR, expressed gratitude to all who have contributed to NIHR research over the past year. She stated: "This annual report spotlights where NIHR research has made a tangible difference to people's health outcomes and has contributed to tackling health inequalities. "Through our partnership working, in 2024/25 and beyond, we will continue to ensure that research will be playing its part in driving the Government's Health and Growth Mission to build a health and care system fit for the future."

The NIHR Research Delivery Network (RDN) has published a new paper highlighting the learnings from a major COVID-19 research trial conducted in primary care settings. The paper, which draws on insights from the PANORAMIC study, emphasised the importance of prioritising primary care studies from the very start of any pandemic to prevent worsening of patient symptoms and reduce hospital admission. Additionally, it recommended considering the use of UK-wide pharmacy networks, including community pharmacies, to promote research inclusion for future similar trials in primary care to increase recruitment in underserved communities. Authored by Professor Phil Evans, GP and Deputy Health and Care Director at the NIHR RDN together with colleagues from the NIHR and University of Oxford, the 80-page paper concluded that primary care research should be at the forefront of future pandemic preparedness. During the early stages of the COVID-19 pandemic, much research was carried out on critically ill patients in secondary care settings.

A groundbreaking immunotherapy for non-small cell lung cancer (NSCLC) is being trialed in the UK for the first time, with the NIHR UCLH Clinical Research Facility (CRF) as the lead research site. Developed by German biotech firm BioNTech, the new vaccine, named BNT116, can prime the immune system to recognise and combat cancer cells. Janusz Racz, a 67-year-old lung cancer patient from London, was the first participant to receive this new vaccine. According to Siow Ming Lee, a UCLH consultant medical oncologist who is leading the national study, lung cancer remains the leading cause of cancer deaths worldwide, with an estimated 1.8 million deaths reported in 2020 "We are now entering this very exciting new era of mRNA-based immunotherapy clinical trials to investigate the treatment of lung cancer," he said. Supported by the NIHR Biomedical Research Centre at UCLH, the study aims to evaluate the safety and tolerance of the immunotherapy, its efficacy in targeting tumours on its own, and its potential to enhance the effectiveness of established chemotherapy or immunotherapy treatments.